Skin Tech Pharma Group's flagship injectable, RRS® HA LONG LASTING, has been named Best Injectable in the Skin Revitalization category at the AMWC Aesthetic Medicine Awards 2026. This recognition underscores the product's role in the emerging Skin Builder category, offering overseas distributors and clinic buyers a differentiated solution that combines skin quality improvement with natural-looking restoration.
Award significance
The AMWC Aesthetic Medicine Awards are among the most prestigious in aesthetic medicine. RRS® HA LONG LASTING was recognized for its contribution to advancing regenerative aesthetic medicine, reflecting growing demand for treatments that deliver natural outcomes while supporting long-term skin health and tissue quality. Since its 2021 launch, over 1 million treatments have been performed worldwide, demonstrating strong safety and clinical performance.
Product positioning
RRS® HA Long Lasting is positioned as neither a skin booster nor a dermal filler, but as a cross-linked hyaluronic acid skin builder combined with a protective buffer of 15 amino acids. It targets both skin quality and natural facial volume restoration within a single treatment, offering immediate visible effects and progressive improvement in skin texture, firmness, and luminosity. This dual-action approach addresses skin ageing holistically.
Clinical perspective
Dr. Javed Hussain, Key Opinion Leader for Skin Tech Pharma Group, notes that clinical use has shown consistent improvements in skin texture, elasticity, and overall luminosity. The product's hyaluronic acid structure combined with amino acid buffer provides essential components for restoring natural dermal function, which declines with age. Outcomes are described as reproducible, reliable, and aligned with established safety expectations, with durability beyond traditional skin boosters.
What buyers should watch
For importers and clinic buyers evaluating injectable portfolios, RRS® HA Long Lasting represents a distinct category that may appeal to patients seeking natural-looking results with progressive skin quality improvement. Its CE-marked status and over 1 million treatments provide a track record for regulatory and clinical due diligence. The award may enhance brand recognition and patient demand in markets where AMWC carries influence.
Company background
Skin Tech Pharma Group, founded in 1994 by Dr. Philippe Deprez and based in Costa Brava, Spain, is privately owned by Charterhouse Capital Partners and EXCELSIS. The company produces CE-marked medical devices and advanced cosmeceuticals, operating an in-house laboratory with a global R&D team. Its 30-year history includes the 1996 launch of Easy TCA®, which established the company as an industry pioneer.
Source: Read the original report | Published: June 17, 2026